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Edited by Ivan SadowskiAbstract GTF2IRD1 is a member of a family of transcription
factors whose deﬁning characteristic is varying numbers of a he-
lix–loop–helix like motif, the I-repeat. Here, we present func-
tional analysis of human GTF2IRD1 in regulation of three
genes (HOXC8, GOOSECOID and TROPONIN ISLOW). We
deﬁne a regulatory motif (GUCE–GTF2IRD1 Upstream Con-
trol Element) common to all three genes. GUCE is bound
in vitro by domain I-4 of GTF2IRD1 and mediates transcrip-
tional regulation by GTF2IRD1 in vivo. Deﬁnition of this site
will assist in identiﬁcation of other downstream targets of
GTF2IRD1 and elucidation of its role in the human developmen-
tal disorder Williams–Beuren syndrome.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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isoforms1. Introduction
The TFII-I family of transcription factors comprises three
members (GTF2I (encoding TFII-I), GTF2IRD1 and
GTF2IRD2) all mapping to the region of chromosome 7
hemizygously deleted in the multisystem disorder Williams–
Beuren syndrome (WBS) [1]. Our human and mouse studies
have associated GTF2IRD1 with craniofacial development [2]
and evidence from patient studies implicates the other family
members, particularly GTF2I, in the main clinical pathology
of WBS [3–8].
Each of the TFII-I transcription factors has a putative leu-
cine zipper (LZ) (a dimerisation motif) at the N-terminus
and varying numbers of a repeated domain, known as an I-re-
peat [9,10]. The I-repeats are of particular interest since the do-
mains appear to have DNA binding properties [11–14] and
their predicted secondary structure indicates that the mecha-
nism may be novel. Studies of the founder member, TFII-I,
have shown that, although the I-repeats are capable of weak
DNA binding [13], speciﬁcity of the protein for E-box se-
quences appears to be mediated through a basic region up-
stream of I-repeat 2, with the I-repeats involved in*Corresponding author. Fax: +44 0 161 276 6606.
E-mail address: m.tassabehji@manchester.ac.uk (M. Tassabehji).
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.02.040homomeric interactions [15]. Functional studies on
GTF2IRD1 in diﬀerent species have shown that it binds to a
number of regulatory elements upstream of genes involved in
tissue development/diﬀerentiation. Xenopus GTF2IRD1
(XWBSCR11) acts as a positive regulator of Xenopus goose-
coid in response to activin [12]; mouse Gtf2ird1 (BEN) inter-
acts with a fragment of Hoxc8 early enhancer [16] and plays
a role in regulation of the mouse IgG variable heavy (IgGVH)
promoter through a speciﬁc downstream regulatory element,
DICE [17]; GTF2IRD1 binds to an element (USEB1), up-
stream of human Troponin ISLOW (TnISLOW) and is necessary
for high level expression of the gene in slow twitch muscle ﬁ-
bres [18]. GTF2IRD1 and TFII-I are thought to interact in
regulation of transcription through the c-fos, IgGVH, goose-
coid and VFGFR2 promoters [17,19–21]. Both proteins also
interact with HDAC3 and PIASxb (a member of the E3 ligase
family involved in the small ubiquitin-like modiﬁer (SUMO)
pathway), implicating them in transcription regulation
through alteration of chromatin structure [22].
Deﬁning the DNA binding sites for a transcription factor
and understanding how a regulatory protein occupies its sites
in vivo is central to understanding gene regulation. In this
study we deﬁne a highly conserved DNA element, GUCE
‘GTF2IRD1 Upstream Control Element’, common to three
genes regulated by GTF2IRD1 by a combination of compara-
tive sequence analysis and both in vitro and in vivo binding as-
says. Binding of GTF2IRD1 to GUCE in vitro is mediated
through protein domain I-4. Semi-quantitative analysis of
the binding of I-4 to wild type and mutated GUCE sequences
suggest the sequence is key for DNA recognition by I-4
in vitro. Recombinant reporter and CHIP assays demonstrate
its importance for site recognition by GTF2IRD1 in vivo.2. Materials and methods
2.1. Sequence alignments
Sequences upstream of Goosecoid, Troponin ISLOW and Hoxc8 cod-
ing regions were isolated from Genbank (where available), screened for
the GUCE consensus and aligned using ClustalW (Supplementary
methods A1).
2.2. Antibody production
Polyclonal antibodies were raised in rabbits to the region of human
GTF2IRD1 between I-2 and I-3 and to a speciﬁc peptide within the N-
terminal domain of GTF2IRD2 (Antibody Resource Centre, UK).
GTF2IRD1 antibody was puriﬁed from crude serum by ammonium
sulphate precipitation followed by aﬃnity chromatography on ablished by Elsevier B.V. All rights reserved.
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binant GTF2IRD1 peptide antigen.
2.3. Western blots and peptide blocking
Western blots of cell lysates were blocked for 16 h (4 C in 10%Mar-
vel in 1· TTBS) prior to incubation with antibodies to GTF2IRD1
(3 lg/ml) GTF2IRD2 (1:5000) or TFII-I (Transduction laboratories;
1:500) in 10% Marvel, 1 · TTBS, 2 h, room temperature. For peptide
blocking the antibody was pre-incubated for 1 h in blocking solution
with an excess (0.1 mg/ml) of the puriﬁed GTF2IRD1. For GAPDH
antibody (Abcam) the antibody was diluted 1:10000. Secondary anti-
bodies were goat anti-rabbit-HRP (Biosource) and sheep anti-mouse
(Amersham Bioscience).
2.4. Chromatin immunoprecipitation
Experiments were carried out using 293HEK cells cultured in
DMEM (Invitrogen) supplemented with 10% FBS, or human primary
muscle cells cultured according to supplier’s instructions (Promocell)
and our GTF2IRD1 antibody or GAPDH antibody (Abeam), using
published protocols [23].
2.5. PCR and QPCR
PCR was carried out using Reddy Mix PCR mix (Applied Biosys-
tems) and Green JumpStart Taq Ready Mix (Finnzymes) was used
for qPCR assays. Primers and cycling conditions are detailed in sup-
plementary methods (A2).
2.6. DNA/protein expression constructs
The human cDNA clones GTF2IRD1b and c (gi: 3913745 and gi:
18776294) were cloned into pCDNADEST40 (Invitrogen) for mamma-
lian expression. GTF2IRD1a was engineered from GTF2IRD1b and c.
GTF2IRD1aDI4 was engineered from GTF2IRD1a and encodes a pro-
tein with amino acids 664–786 deleted and 662–663 altered (‘LV’ ﬁ
‘VI’). Bacterial expression constructs were engineered using PCR prod-
ucts ampliﬁed from GTF2IRD1b and cloned into pDEST17 or
pDEST15 (Invitrogen). Tagged peptides were expressed in E. coli
and puriﬁed by aﬃnity chromatography.
For the HOXC8 reporter construct, sense – 5 0-GATCTAAATC-
GGATTATAGGAAATCGGATTATAGGAAATCGGATTATAG-
GG-3 0 and antisense-5-GATCCCCTATAATCCGATTTCCTATA-
ATCCGATTTCCTATAATCCGATTT-3 0 oligonucleotides were 5 0
phosphorylated, annealed and two copies cloned into pGL3promoter
(Promega). HOXC8MUT and HOXC8LIMUT reporter constructs
contained mutations within the GUCE motifs (Fig. 6).
pGL3GSCProm was constructed by cloning a PCR ampliﬁed DNA
fragment encompassing the human GSC promoter (nt-443 to +34) into
the XhoI/HindIII sites of pGL3Basic (Promega).
2.7. Gel shift assays
Oligonucleotides used: HOXC8-Sense 5 0-CTGGCACTTTCCTT-
TGAAATCGGATTATA-3 0, HOXC8-Antisense 5 0-GTGGTATAAT-
CCGATTTCAAAGGAAAGTG-3 0. Gel shifts were carried out at
50 mM KC1 essentially as described previously [24].
2.8. Circular dichroism
GTF2IRD1-I4-GST and GST peptides (at 0.3–0.5 mg/ml in buﬀer
containing 50 mM NaCl and l0 mM phosphate) were loaded onto a
0.5 mm path-length cuvette (Starna). Circular dichroism spectra were
analyzed at 20 C between wavelengths of 260 and 190 nm on a Jasco
J810 model circular dichroism spectrometer at 0.5 nm, 0.5 s response
and are the average of 10 accumulations.
2.9. Quantitative gel shift assays
Wild type and mutated DNA fragments were prepared by annealing
equimolar concentrations of sense and antisense oligonucleotides.
DNA duplexes (50 pmol) were end-labelled with [c-32P] ATP and puri-
ﬁed on Sephadex G50 columns (Amersham Biosciences). Following
ethanol precipitation, the probes were resuspended in 10 mM Tris–
HCl (pH 7.0), 50 mM NaCl. Binding was for 15 min at room temper-
ature (in 10 mM Tris (pH 7.8), 50 mM NaCl, 5% glycerol and 1 mM
DTT) with increasing amounts of protein (0, 0.1, 0.2, 0.5, 1, 2, 3,
and 4 lM) incubated with a ﬁxed concentration (250 nM) of labelled
double stranded DNA in a ﬁnal reaction volume of 10 ll. The reac-tions were resolved by electrophoresis on 6% non-denaturing poly-
acrylamide/TAE gels. The fraction of bound DNA was determined
by quantitation of unbound probe in the dried gels [25] using electronic
autoradiography (Packard Instant Imager).
2.10. Luciferase assays
293HEK cells were transfected with 6 ll Polyfect (Qiagen) per trip-
licate and a total of 800 ng DNA per well in 12 well plates. Luciferase
levels were normalised for transfection eﬃciency by co-transfection of
the control b-galactosidase pCH110 plasmid (Pharmacia) and activities
of both were measured using the Dual-light luciferase assay system
(Applied Biosystems) as described previously [26].3. Results
3.1. Identiﬁcation of a putative binding site for GTF2IRD1
Analysis of the sequence of promoters regulated by
GTF2IRD1 and its homologues (Xenopus Goosecoid DE,
mouse Hoxc8 enhancer element, rat TnISLOW SURE and hu-
man TnISLOWUSEB1) [12,16,18,27] identiﬁed a conserved 10
nucleotide motif of ‘5 0-AYMRGATTAW-3 0 present in all of
them. Phylogenetic footprints were generated by aligning the
motif in the context of ﬂanking sequences upstream of the
genes Hoxc8, Goosecoid and TnISLOW using sequences avail-
able in the databases (Fig. 1).
Overall, the evolutionary conservation data suggest a core
conserved site of 5 0-RGATTA-3 0, with strong evidence of fur-
ther conservation in ﬂanking sequences. We called the putative
5 0-AYNRGATTAWM-3 0 DNA binding element, GUCE –
‘GTF2IRD1 Upstream Control Element’ (Fig. 1D).
3.2. Endogenous human GTF2IRD1 localises to GUCE-
containing chromosomal regions in vivo
We performed chromatin immunoprecipitation (ChIP) to
determine whether endogenous GTF2IRD1 is associated with
the human regulatory elements containing GUCE in vivo.
Initially, we assessed the speciﬁcity of our antibody. Western
blots from untransfected 293HEK and COS7 cell lysates iden-
tiﬁed a 115 kDa band (expected size), and three smaller
bands of 75, 45 and 40 kDa, (Fig. 2Ai, lanes 1 and 3).
293HEK and COS7 cells transfected with a construct express-
ing full length, native GTF2IRD1 displayed more intense
bands co-migrating with the 115 and 75 kDa endogenous
proteins (Fig. 2Ai, lanes 2 and 4). Speciﬁcity of the bands
was conﬁrmed by incubating the primary antibody with the
GTF2IRD1 peptide antigen prior to Western blotting. After
this treatment no bands were detected in either transfected
or untransfected cells (Fig. 2Ai, lanes 5–8). This indicates that
the observed bands are isoforms of GTF2IRD1, with the
115 kDa band likely representing the full length protein and
demonstrates both the presence of endogenous GTF2IRD1
in these cells and speciﬁcity of the antibody.
The GTF2IRD1 peptide antigen was designed to avoid the
regions with greatest similarity to other members of the
TFII-I family of proteins (i.e. the I-repeats and the leucine zip-
per). GTF2IRD1 antibody speciﬁcity was demonstrated on a
western blot comprising of 3 identical lanes with equal
amounts of 293HEK cell lysates; each was probed with an
antibody against one of the family members. No TFII-I or
GTF2IRD2 bands were detected with the GTF2IRD1 anti-
body (see Fig. 2Aii). Protein/DNA complexes were isolated
from 293HEK cells and interrogated using ChIP assays.
Fig. 1. Conservation of upstream elements containing the putative GTF2IRD1 binding site. Predicted GTF2IRD1 recognition sites located within
the regulatory regions upstream of the genes are shown in blue. Identical nucleotides are starred and non-conserved bases shown in lower-case.
Alignments of regulatory elements upstream of: (A) Goosecoid (B) TnISLOW and (C)Hoxc8 – numbers in brackets indicate nucleotide gaps in two ﬁsh
species between the 5 0 Hoxc8 enhancer element and GUCE containing sequences. (D) Comparison of the putative GTF2IRD1 consensus across the
diﬀerent regulatory elements: (i) Nucleotides conserved between two of the three promoter regions are shaded. (ii) Sequence logo of the GUCE
consensus using ‘‘Weblogo’’[33]. Height of letters correlates with degree of conservation.
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from the human GUCE-containing regions and control prim-
ers to a genomic region ﬂanking the Calneuron gene (CALN).
Enrichment of DNA from the three GUCE-containing ele-
ments, but not the control, in DNA isolated with GTF2IRD1
was observed. Although the presence of each of the three ele-
ments before immunoprecipitation was conﬁrmed (Input),
ChIP assays using a control antibody (GAPDH) resulted in
only very weak (background) ampliﬁcation in each case
(Fig. 2Bi).
In addition, complexes were isolated from cultured human
primary skeletal muscle cells. Quantitative PCR demonstrated
enrichment for a fragment containing the GUCE element up-
stream of TnISLOW when DNA isolated with the GTF2IRD1
antibody was used as a template, but not with the DNA
associated with the GAPDH antibody. Again, no enrichment
of the control genomic region (CALN) was observed
(Fig. 2Bii).
Overall, these results suggest that endogenous human
GTF2IRD1 is present at GUCE-containing sites in vivo under
basal cell culture conditions.3.3. Identiﬁcation of a GTF2IRD1 GUCE-binding domain
In vitro gel shift assays were used to determine whether
GTF2IRD1 interacts directly with GUCE and to identify the
protein domain(s) involved. I-repeats (I-1–I-5) and the C-ter-
minus region were puriﬁed as tagged peptides (Fig. 3A). Pep-
tide I-4 was suﬃcient to bind to a human HOXC8 GUCE
25 bp oligonucleotide probe (Fig. 3B). Peptide I-3 also dis-
played weak shifts on the HOXC8 probe which may be due
to non-speciﬁc DNA interactions since, unlike I-4, it also
bound to a control non-speciﬁc probe tested alongside (data
not shown). Sequence alignments of the I-repeats from all
TFII-I family members highlight greater similarities between
GTF2IRD1 repeat I-4, TFII-I repeat I-6 and GTF2IRD2 re-
peat I-2 compared to any of the other I-repeats [10], which
may explain the selective binding properties of the I-4 domain
for GUCE demonstrated here (Fig. 3C).
3.4. Semi-quantitative DNA binding analysis
To further delineate the interactions between the I-4 domain
and the conserved GUCE motif, semi-quantitative DNA bind-
ing assays using puriﬁed GST-tagged I-4 were performed.
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Fig. 2. Endogenous GTF2IRD1 localises to chromosomal sites containing GUCE. (A) Speciﬁcity of GTF2IRD1 antibody. (i) Western blots of
whole COS7 (lanes 1–2 and 5–6) or 293HEK (lanes 3–4 and 7–8) cell lysates probed with GTF2IRD1 antibody, either unblocked (lanes 1–4) or
blocked with excess peptide antigen (lanes 5–8); either untransfected (lanes 1, 3, 5, 7) or transfected with a construct expressing full length
GTF2IRD1 (lanes 2, 4, 6, 8). * indicates a shorter exposure time for lane 4. The lower panel shows the blots probed with GAPDH antibody, (ii)
Western blot demonstrating that antibody to GTF2IRD1 does not react to TFII-I family members. Whole cell lysates (30 lg total protein) from
293HEK cells probed with antibodies speciﬁc for TFII-I, GTF2IRD1 or GTF2IRD2. The bands detected by each antibody do not co-migrate with
one another. (B) Chromatin immunoprecipitation assays, (i) Ampliﬁcation products from control (CALN) or GUCE containing regulatory elements.
Lanes: 1, input control; 2, GAPDH control antibody; 3, GTF2IRD1 speciﬁc antibody. (ii) Results of quantitative PCR of using template DNA co-
immunoprecipitated from human primary skeletal muscle cells using GTF2IRD1 or a control (GAPDH) antibody. There is clear enrichment for the
chromosomal region encompassing the GUCE motif upstream of TnISLOW, but not the control (CALN) region.
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lysed by circular dichroism (CD) spectroscopy to ensure that
it adopted a folded conformation. To assess the relative con-
tent of secondary structure, deconvolution of the CD data
for both GST-I4 and GST alone was performed using the
CDSSTR algorithm [28] (Dichroweb). The GST protein alone
showed a typical a-helical pattern with minima at 222 and
208 nm with evidence of some b-strand and random coil which
is consistent with the known structure of the molecule. Com-
parison with the GST-I4 fusion protein showed a change in
the overall structure. The structure of the GST-I4 fusion pro-
tein appears to have more b-sheet content, with a decrease in
overall alpha helices and a similar fraction of random coil,
indicating that the domain used in the binding assays has sec-
ondary structure elements consistent with a folded domain
(Fig. 4A).To deﬁne the important residues from the predicted consen-
sus GUCE element, increasing amounts of I-4 were titrated
against a ﬁxed amount of each of 14 (one wild type GUCE
and 13 mutated) radio-labelled oligonucleotide probes
(13 bp) spanning the human GSC GUCE, and the binding
aﬃnity compared (Fig. 4B). As expected, the control GST pep-
tide did not show any evidence of DNA binding.
The fraction of bound oligonucleotide was plotted against
log10 protein concentration (nM) and the mean concentration
at which 50% of the oligo was bound was used to estimate dis-
sociation constants (Kds) for each of the 14 DNA duplexes
(Fig. 4C). The Kd for WT GUCE was estimated as
0.474 ± 0.06 lM. Other than mutation M1, which I-4 bound
with a similar aﬃnity to WT (Kd 0.434 ± 0.19 lM) all of
the mutations within the predicted consensus resulted in some
decrease in aﬃnity of I-4 for the DNA. Mutation of the ‘T’ at
12
2
21
0
34
4
43
1
55
5
64
9
69
8
78
8
79
6
88
3
88
2
95
9
GTF2IRD1
I-1        I-2 I-3 I-4        I-5  CTR
A B
(i)  
GTF2IRD1_I4          QGFQENYDARLSRIDIANTLREQVQDLFNKKYGEALGIKYPVQVPYKRIKSNPGSVIIEGLPPGIPFRKPCTFGSQNLERILAVADKIKFTVTRPFQGLIPKPDED 
GTF2I_I6             VTIPDDDNERLSKVEKARQLREQVNDLFSRKFGEAIGMGFPVKVPYRKITINPGCVVVDGMPPGVSFKAPSYLEISSMRRILDSAEFIKFTVIRPFPGLVINNQLV   
GTF2IRD2_I2          VTVPDNEKERLSSIEKIKQLREQVNDLFSRKFGEAIGVDFPVKVPYRKITFNPGCVVIDGMPPGVVFKAPGYLEISSMRRILEAAEFIKFTVIRPLPGLELSNVGK
GTF2IRD1_I5          GLIPKPDEDDANRLGEKVILREQVKELFNEKYGEALGLNRPVLVPYKLIRDSPDAVEVTGLPDDIPFRNPNTYDIHRLEKILKAREHVRMVIINQLQPFAEICNDA
GTF2IRD1_I2          HDKSEKWDAFIKETEDINTLRECVQILFNSRYAEALGLDHMVPVPYRKIACDPEAVEIVGIPDKIPFKRPCTYGVPKLKRILEERHSIHFIIKRMFDERIFTGNKF
GTF2I_I2             GKRKVREFNFEKWNARITDLRKQVEELFERKYAQAIKAKGPVTIPYPLFQSHVEDLYVEGLPEGIPFRRPSTYGIPRLERILLAKERIRFVIKKHELLNSTREDLQ
GTF2I_I5             FKPRGREFSFEAWNAKITDLKQKVENLFNEKCGEALGLKQAVKVPFALFESFPEDFYVEGLPEGVPFRRPSTFGIPRLEKILRNKAKIKFIIKKPEMFETAIKEST
GTF2I_I3             QLDKPASGVKEEWYARITKLRKMVDQLFCKKFAEALGSTEAKAVPYQKFEAHPNDLYVEGLPENIPFRSPSWYGIPRLEKIIQVGNRIKFVIKRPELLTTHSTTEV
GTF2I_I4             TQPRTNTPVKEDWNVRITKLRKQVEEIFNLKFAQALGLTEAVKVPYPVFESNPEFLYVEGLPEGIPFRSPTWFGIPRLERIVRGSNKIKFVVKKPELVISYLPPGM
GTF2IRD1_I3          DARPEERPVEDSHGDVIRPLRKQVELLFNTRYAKAIGISEPVKVPYSKFLMHPEELFVVGLPEGISLRRPNCFGIAKLRKILEASNSIQFVIKRPELLTEGVKEPI
GTF2I_I1             MKSTTQANRMSVDAVEIETLRKTVEDYFCFCYGKALGKSTVVPVPYEKMLRDQSAVVVQGLPEGVAFKHPENYDLATLKWILENKAGISFIIKRPFLEPKKHVGGR
GTF2IRD2_I1          VKPPCPVNGMQVHSGETEILRKAVEDYFCFCYGKALGTTVMVPVPYEKMLRDQSAVVVQGLPEGVAFQHPENYDLATLKWILENKAGISFIINRPFLGPESQLGGP
GTF2IRD1_I1          GGGRSLPRSSLEHGSDVYLLRKMVEEVFDVLYSEALGRASVVPLPYERLLREPGLLAVQGLPEGLAFRRPAEYDPKALMAILEHSHRIRFKLKRPLEDGGRDSKAL
                                        *:: *.  *    .:*:       :*:  :      . : *:*  : :: *       :  *:     : : : . 
(ii) 
H-L-H superposition33                            Helix  1                                          Loop                                                    Helix 2                       
GTF2IRD1_I4           QGFQENYDARLSRIDIANTLREQVQDLFNKKYGEALGIKYPVQVPYKRIKSNPGSVIIEGLPPGIPFRKPCTFGSQNLERILAVADKIKFTVTRPFQGLIPKPDED
GTF2I_I6              VTIPDDDNERLSKVEKARQLREQVNDLFSRKFGEAIGMGFPVKVPYRKITINPGCVVVDGMPPGVSFKAPSYLEISSMRRILDSAEFIKFTVIRPFPGLVINNQLV
GTF2IRD2_I2           VTVPDNEKERLSSIEKIKQLREQVNDLFSRKFGEAIGVDFPVKVPYRKITFNPGCVVIDGMPPGVVFKAPGYLEISSMRRILEAAEFIKFTVIRPLPGLELSNVGK
                        . :: . *** ::  . *****:***.:*:***:*: :**:***::*. ***.*:::*:***: *: *  :  ..:.***  *: ***** **: **  .   
PSI-PRED prediction 
C
BL
AN
K
I-1 I-2 I-3 I-4 I-5 C
TR
Fig. 3. GTF2IRD1 binds GUCE via I-4 in vitro. (A) Schematic of GTF2IRD1 (gi: 6635333) showing amino acid residues cloned and expressed in
E. coli for band shift assays. I-1 = Aa residues 122–210; I-2 = residues 344–431; I-3 = residues 555–649; I-4 = residues 698–788; 1-5 = residues 796–
883; C-terminal region (CTR) = residues 882–959. (B) Gel mobility shift assays of 32P-labelled oligonucleotide probes from the HOXC8 upstream
enhancer. Lanes: 1, no peptide control; 2–6, domains; 11–15, respectively; 7, GTF2IRD1-CTR.
P.D. Thompson et al. / FEBS Letters 581 (2007) 1233–1242 1237position 8 (M10) is particularly detrimental, resulting in an
approximately four-fold decrease in the aﬃnity of I-4 for the
sequence (Kd 2.109 ± 0.41 lM). Surprisingly, due to the lack
of evolutionary conservation, changing the nucleotide at posi-
tion 3 from ‘G’ to ‘C’ (M4) also has a marked eﬀect on the
DNA binding aﬃnity of I-4. This may reﬂect species speciﬁcity
of human GTF2IRD1 for its cognate GSC site. Mutation of
the ‘W’ (A/T) at position 10 has only a marginal eﬀect on aﬃn-
ity of I-4 (Kd 0.786 ± 0.42) which is unlikely to be signiﬁcant.
Therefore, based on these binding studies alongside evolution-
ary conservation data, we propose a consensus of 5 0-AYNR-
GATTANM-3 0 for I-4 of GTF2IRD1.
3.5. All known isoforms of GTF2IRD1 can repress transcription
through GUCE
Two splice variants of human GTF2IRD1 have been charac-
terised previously and are referred to here as the a (gi:4680483,
[29]) and b (gi:6635332, [30]) isoforms (predicted Mw 105 and
106 kDa respectively), the latter having a 45bp extension ofexon 19 (encoding 15 amino acids) relative to the former.
We have identiﬁed another isoform, designated GTF2IRD1c
(gi: 49781271) through database searches. This human cDNA
clone isolated from adult hippocampus (gi: 18776294) contains
an additional 96 bp of sequence (an extension of exon 4) giving
a predicted protein size of 108 kDa. Sequences of GTF2IRD1
orthologues demonstrate strong conservation in vertebrate
species including mammals, birds, amphibians and ﬁsh. How-
ever, the peptide sequences encoded by alternative splicing are
less well conserved. There is evidence for the presence of both
extended exons in primates, and also of the extended exon 19
(GTF2IRD1b) in cattle (Fig. 5), however, neither exon is dis-
cernible in rodents (M. musculus, R. norvegicus) or other verte-
brates.
Reporter assays were carried out to determine the role of the
GUCE element in mediating transcriptional control by
GTF2IRD1 in vivo. Luciferase reporter constructs containing
6 · 15 bp HOXC8 GUCE elements were prepared (pGL3-
HOXC8). Co-transfection of plasmids expressing the
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M7 3 cctcAATGAGgTTAACCtcg 1.128 ± 0.34 
M8 5 cctcAATGAGAggAACCtcg 2.160 ± 1.05 
M9 3 cctcAATGAGAgTAACCtcg 1.291 ± 0.35 
M10 2 cctcAATGAGATgAACCtcg 2.109 ± 0.41 
M11 3 cctcAATGAGATTgACCtcg 1.352 ± 0.22 
M12 4 cctcAATGAGATTAgCCtcg 0.786 ± 0.42 
M13 5 cctcAATGAGATTAAgCtcg 0.955 ± 0.10 
Spectral Analysis by CDSSTR
GST-I4 GST
α-HELIX 0.16 0.30
β-SHEET 0.55 0.40
UNORDERED 0.30 0.29
TOTAL 1.01 0.99
1   2   3   4   5   6   7   8   9   10  11
EVOLUTIONARY CONSENSUS A   Y   N   R   G   A   T   T   A    W   M
BASES IMPORTANT FOR I-4 BINDING A   Y   N   R   G   A   T   T   A    N   M
C
WTWT
M1
M2
M3
M4
M5
M6
M8
M9
M7
M11
M12
M13
M10
GSTGST-I-4
 K(i)
(ii)
Fig. 4. (A) Circular dichroism spectra of GST alone (black line) and GST-I4 fusion protein (red line). Table shows CDSSTR analysis. (B)
Representative gels used for semi-quantitative DNA binding analysis of I-4 to wild type GUCE (WT) and mutated (M1–M13) DNA probes
(oligonucleotide sequences in C). The ﬁrst lane is a no peptide control and the subsequent lanes show 32P-labelled DNA incubated with increasing
concentrations of GST or GST-I4 (0.1, 0.2, 0.5, 1.0, 2.0, 3.0 and 4.0 lM). (C) (i) Table showing Kd values calculated from semi-quantitative DNA
binding analysis (N indicates the number of replicates). (ii) Comparison of the consensus sequences derived from the evolutionary and binding
studies.
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sion of luciferase activity in each case (Fig. 6A).
3.6. Deletion of domain I-4 diminishes, but does not abolish,
transcription repression by GTF2IRD1
To determine the role of I-4 in GTF2IRD1 mediated tran-
scriptional regulation a mutated form of GTF2IRD1a lacking
amino acids 664–786 (GTF2IRD1aDI4) was constructed and
its ability to modulate transcription from a GUCE containing
reporter construct (pGL3GSCProm) compared to that of the
wild type protein. GTF2IRD1aDI4 retained the ability to
mediate transcriptional repression from the reporter construct,
however, in comparison to the wild type protein, the repression
was signiﬁcantly diminished (Fig. 6B). These results conﬁrm
that I-4 does contribute to transcription regulation by
GTF2IRD1.
3.7. GUCE is necessary for transcription regulation by
GTF2IRD1
To assess the importance of GUCE in transcription regula-
tion by GTF2IRD1 the core element was mutated from 5 0-
GATTA-3 0 to 5 0-CCCCC-3 0 or 5 0-GAAAA-3 0 (constructspGL3-HOXC8MUT and HOXC8LIMUT). These mutations
were suﬃcient to abrogate repression by GTF2IRD1
(Fig. 6C and D) demonstrating the importance of GUCE in
mediating gene regulation by GTF2IRD1.4. Discussion
GTF2IRD1 has recently been shown to play an important
role in craniofacial development [2], however, little is known
about its mechanism of action or downstream targets.
Phylogenetic footprinting, using sequence conservation as
an indicator of functional signiﬁcance, has been used to iden-
tify gene regulatory elements [31] and was adopted here as a
preliminary in silico approach for GTF2IRD1. We identiﬁed
a highly conserved DNA sequence in upstream regions of three
genes previously linked with GTF2IRD1 [12,16,18,27]. Subse-
quent in vitro DNA binding studies using human protein con-
ﬁrmed and deﬁned the DNA motif further, leading to the
consensus 11 bp GUCE site 5 0-AYNRGATTANM-3 0 Domain
I-4 of GTF2IRD1 (Aa 698–788) is involved in binding GUCE,
agreeing with and reﬁning previous studies on the TnISLOW
GTF2IRD1β
H.sapiens alpha 629 ASNSIQFVIKRPELLTEGVKEPIVDSQ---------------ERDSGDPLVDESLKRQ-GF 673
H.sapiens beta      ASNSIQFVIKRPELLTEGVKEPIMDSQGTASSLGFSPPALPPERDSGDPLVDESLKRQ-GF
H.sapiens gamma     ASNSIQFVIKRPELLTEGVKEPIMDSQ---------------ERDSGDPLVDESLKRQ-GF
P.troglodytes (1)   ASNSIQFVIKRPELLTEGVKEPIVDSQ---------------ERDSGDPLVDESLKRQ-GF
P.troglodytes (2)   ASNSIQFVIKRPELLTEGVKEPIVDSQGTASSLGFSPPALPPERDSGDPLVDESLKRQ-GF
P.troglodytes (3)   ASNSIQFVIKRPELLTEGVKEPIVDSQ---------------ERDSGDPLVDESLKRQ-GF
M.mulatta (1)       ASNSIQFVIKRPELLTEGVKEPIVESQ---------------ERDSGDPLVDENLKRQ-GF
M.mulatta (2)       ASNSIQFVIKRPELLTEGVKEPIVESQGTASSLGFSPPALPPERDSGDPLVDENLKRQ-GF
M.mulatta (3)       ASNSIQFVIKRPELLTEGVKEPIVESQ---------------ERDSGDPLVDENLKRQ-GF
B.taurus (1)        ASNSIQFVIKRPELLTEGVKEPLSDSQ---------------ERDSGDPLVDESLKRQ-GF
B.taurus (2)        ASNSIQFVIKRPELLTEGVKEPLSDSQATRSPWLLSPPPTPPERDSGDPLVDESLKRQ-GF
C.familiaris ASNSIQFVIKRPELLTEGVKEPITDSQ---------------ERDSGDPLVDESLKRQ-GF
R.norvegicus ASNSIQFVIKRPELLTDGVKEPVMDTQ---------------ERDSWDPLVDETPKRQ-GL
M.musculus ASNSIQFVIKRPELLTDGVKEPVLDTQ---------------ERDSWDRLVDETPKRQ-GL
X.laevis YSDGIQFVVKRPELISEGLEDCVVGSPGTLG----------FNDKSNEVILDETNTRP-SF
G.gallus HSHSIRFRLKRPADEPSREPNPSVELTCTS----------LVPKGGRDPGANSHTAKPSGQ
T.nigroviridis AGSHIQFVIKRPELLSEQVKQEVPSNS---------------VCDSATEDGAALSKRP-GF
                      .  *:* :***   ..   :                        .          :  . 
H.sapiens beta      ASNSIQFVIKRPELLTEGVKEPIMDSQGTASSLGFSPPALPPERDSGDPLVDESLKRQGF
P.troglodytes ASNSIQFVIKRPELLTEGVKEPIVDSQGTASSLGFSPPALPPERDSGDPLVDESLKRQGF
M.mulatta ASNSIQFVIKRPELLTEGVKEPIVESQGTASSLGFSPPALPPERDSGDPLVDENLKRQGF
B.taurus ASNSIQFVIKRPELLTEGVKEPLSDSQATRSPWLLSPPPTPPERDSGDPLVDESLKRQGF
                     **********************: :**.* *.  :***. *************.****** 
GTF2IRD1Y
H.sapiens alpha  70 GRMFLNARKELQSDFLRFCR--------------------------------GPPWKDPE 97
H.sapiens beta      GRMFLNARKELQSDFLRFCR--------------------------------GPPWKDPE
H.sapiens gamma     GRMFLNARKELQSDFLRFCLSAAQHRAATSQLEGRVVRRVLTVASRALCPTGGPPWKDPE
P.troglodytes (1)   GRMFLNARKELQSDFLRFCR--------------------------------GPPWKDPE
P.troglodytes (2)   GRMFLNARKELQSDFLRFCR--------------------------------GPPWKDPE
P.troglodytes (3)   GRMFLNARKELQSDFLRFCLSAAQHRAETSQLEGRVVRRVLIVASHALCPTGGPPWKDPE
M.mulatta (1)       GRMFLNARKELQSDFLRFCR--------------------------------GPPWKDPE
M.mulatta (2)       GRMFLNARKELQSDFLRFCR--------------------------------GPPWKDPE
M.mulatta (3)       GRMFLNARKELQSDFLRFCPSTAPHRAETSQLEGRLVRWVFTVASRAVCPTGGPPWKDPE
B.taurus (1)        GRMFLNARKELQSDFLRFCR--------------------------------GAPWKEPE
B.taurus (2)        GRMFLNARKELQSDFLRFCR--------------------------------GAPWKEPE
C.familiaris GRMFLNARKELQSDFLRFCR--------------------------------GAPWKEPE
R.norvegicus GRVFLNTRKELQSDFLRFCR--------------------------------GPLWNDPE
M.musculus GRVFLNTRKELQSDFLRFCR--------------------------------GPLWNDPE
X.laevis GRCFLNSRKELQADFQRFCI--------------------------------GAHKKDQE
G.gallus GRVFLSARKELQADFQKFCRVQQRREQD-----------------------AEAQKKAKE
T.nigroviridis GRVFLNSRREIQTDFYKFCRVPCLQN----------------------VTAATAHTKDKE
                     ** **.:*:*:*:** :**                                  .  :  * 
H.sapiens gamma GRMFLNARKELQSDFLRFCLSAAQHRAATSQLEGRVVRRVLTVASRALCPTGGPPWKDPE
P.troglodytes GRMFLNARKELQSDFLRFCLSAAQHRAETSQLEGRVVRRVLIVASHALCPTGGPPWKDPE
M.mulatta GRMFLNARKELQSDFLRFCPSTAPHRAETSQLEGRLVRWVFTVASRAVCPTGGPPWKDPE
                     ******************* *:* *** *******:** *: ***:*:************ 
A
B
Fig. 5. Alignments of GTF2IRD1 peptide sequences encoded by alternatively spliced isoforms (GTF2IRD1b and c). Sequences (Accession numbers
in Supplementary methods A3) were compiled in FASTA format and aligned using ClustalW.
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tif) which demonstrated the binding properties of I-4 (Aa 544–
786) [11]. The demonstration that, of GTF2IRD1 I-repeats,
only I-4 appears to interact speciﬁcally with GUCE is interest-
ing in light of the fact that our analyses of I-repeats, from all
TFII-I family members in both human and mouse, place I-4
in a separate clade (along with I-2 of GTF2IRD2 and I-6 of
TFII-I) from other GTF2IRD1 I-repeats and highlight speciﬁc
amino acid diﬀerences within I-4 which may play a functional
role [10]. We have demonstrated the functional signiﬁcance of
I-4’s DNA binding capabilities by showing that a mutated
form of GTF2IRD1a lacking I-4 has a reduced ability to re-
press transcription from a reporter construct containing
GUCE. This data conﬁrms and extends work using an I-4-
VP16 fusion construct to activate transcription from the
TnISLOW GUCE containing element [13]. However, although
both sets of data conﬁrm the functional signiﬁcance of I-4
associated DNA binding, our data also demonstrate that
GTF2IRD1 is capable of transcription repression in the ab-
sence of this domain. This suggests that for full repressive
function either GTF2IRD1 requires the involvement of otherdomains or alternatively the repression may be partially inde-
pendent of DNA binding.
Our data also conﬁrms and extends that obtained by in
vitro SELEX methods [13] which proposes a binding site of
5 0(G/A)GATT(G/A)3 0 for mouse gtf2irdl I-4. In contrast,
our semi-quantitative DNA binding analysis demonstrates
that substituting the last guanine for an adenine in this consen-
sus signiﬁcantly decreases (3-fold) the aﬃnity of human
GTF2IRD1 I-4 for the sequence, which is reinforced by the
strong conservation of this nucleotide within known
GTF2IRD1 target sites. In addition, residues ﬂanking the core
‘RGATTA’ site inﬂuence the binding of I-4 to GUCE. In vivo
chromatin immunoprecipitation (ChIP) conﬁrmed the interac-
tion of endogenous GTF2IRD1 with speciﬁc chromosomal
sites and the GUCE motif was shown to be necessary for
repression of reporter gene expression by GTF2IRD1. Tran-
scription regulation through GUCE appears not to be directly
aﬀected by peptides encoded by the alternatively spliced exons
of the human gene, as all three isoforms of GTF2IRD1 tested
repressed expression of the pGL3-HOXC8 reporter to a similar
extent.
GTF2IRD1α - +     - - GTF2IRD1α - +     - ++     -
GTF2IRD1γ - - +     - GTF2IRD1αΔ  I4 - - +     - ++
GTF2IRD1β - - - +
GTF2IRD1αΔ  I4 - - - -
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Fig. 6. Luciferase assays showing that; (A) all three GTF2IRD1 isoforms can repress through a reporter containing GUCE; (B) domain I-4
contributes to transcription regulation by GTF2IRD1. A reduction in the level of repression from pGL3GSCProm is observed with increasing
concentrations of GTF2IRD1aD-I4 compared with the wild type protein (GTF2IRD1a). (C and D) The GUCE sequence motif is necessary for
repression of the reporter by GTF2IRD1. GTF2IRD1 is only able to repress expression from pGL3HOXC8, containing an intact GUCE motif. 293T
HEK cells were transfected with, pGL3PROM vector, pGL3HOXC8, pGL3GSCProm pGL3HOXC8MUT or pGL3HOXC8LIMUT, either alone or
with DEST40GTF2IRD1a, b, c or aD-I4. Results are expressed as mean(±S.E.M.) of triplicate samples, are representative of at least two independent
experiments and are shown as fold change relative to control experiments ((A) pGL3HOXC8 and (B) pGL3GSCProm reporter constructs alone or
(C) and (D) pGL3PR0M vector alone). Panels below show Western blots of cell lysates used for luciferase assays probed with GTF2IRD1 antibody.
1240 P.D. Thompson et al. / FEBS Letters 581 (2007) 1233–1242The exact role of GTF2IRD1 in regulation of goosecoid is
somewhat contentious. An initial study demonstrated activa-
tion of Gsc by Xenopus GTF2IRD1 in response to Activin
[12]. In contrast, a second study suggested that TFII-I family
proteins oppose one another in the regulation of goosecoid,
with TFII-I activating in response to TGFb/activin signalling
and GTF2IRD1 able to repress this response [21]. The latter
study also demonstrated the constitutive presence of Gtf2ird1
at the Gsc promoter in mouse P19 cells (in the absence of
TGFR signalling), which corroborates our observation that
GTF2IRD1 localises to the GUCE containing element up-stream of this gene in human cells under standard culture con-
ditions.
Mouse gtf2irdl (BEN) can bind to the EFG site within the
early enhancer (EE) of mouseHoxc8 [16] and our data indicate
that the human equivalent of this enhancer motif mediates
transcriptional repression by GTF2IRD1 through the GUCE
consensus. The importance of the Hoxc8 EE for transcrip-
tional control was demonstrated in mutant mouse models de-
leted for the 200 bp Hoxc8 EE (encompassing GUCE) [32]
which showed signiﬁcant delay in the temporal expression of
Hoxc8 and also shares aspects of its phenotype with our
P.D. Thompson et al. / FEBS Letters 581 (2007) 1233–1242 1241Gtf2ird1 null mouse[2]; both display an abnormal clasping of
the limbs when suspended by the tail. This leads us to speculate
that aspects of the neurological phenotypes observed in WBS
could be inﬂuenced by GTF2IRD1 induced misregulation of
HOXC8.
In conclusion, GTF2IRD1 is an interesting and unusual
transcription factor, particularly in light of its role in the path-
ogenesis of WBS, and may facilitate deeper understanding of
the molecular mechanisms underlying human development
and cognition. Deﬁning the novel regulatory element, GUCE,
will help identify other targets of GTF2IRD1 and aid the elu-
cidation of its biological role.
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